Alexza deal with Teva sets stage for Adasuve, say analysts

23 May 2013

USA-based Alexza Pharmaceuticals’ (Nasdaq: ALXA) US marketing deal with Israel-headquartered Teva Pharmaceutical Industries (NYSE: TEVA) for Adasuve (orally-inhaled Staccato loxapine; The Pharma Letter May 9) enhances the product’s US sales prospects given Teva’s expertise in the psychiatric and hospital markets, say analysts at Edison Investment Research.

Adasuve is a potentially disruptive new product for acute agitation in schizophrenia or bipolar disorder, given its advantages over existing options (injection/oral/buccal). The investment case is shifting from a development/regulatory play to one of commercial execution by Adasuve’s licensees, Teva in the USA and Ferrer in Europe, the analysts say.

Teva deal validates Adasuve’s potential

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK